EV-302 Patient-Reported Outcomes
Shilpa Gupta, MD, shares her findings on patient-reported outcomes from the EV-302 clinical trial with Amanda Nizam, MD. Drs. Gupta and Nizam discuss the unique aspects of the trial, highlighting the impact of enfortumab vedotin and pembrolizumab on progression-free survival and overall survival in metastatic urothelial carcinoma. Get the latest updates and insights on advanced urothelial carcinoma at https://guoncologynow.com/page/advanc....
▶︎
Panel Shares Thoughts on EV-302 Study: Response Rate, Toxicities, Progression, and More
▶︎
ASCO26 Preview: Novel Therapies and Innovations in Cancer Care
▶︎
Upper Tract Urothelial Carcinoma Key Challenges and Expert Solutions
▶︎
Emerging Therapies: Bispecifics, PARP Inhibitors, and Novel Radioisotopes
▶︎
Elderly Patients: Single Agent vs. Doublet Chemotherapy
▶︎
Super-KI? Die große Lüge der Tech-Konzerne
▶︎
ASCO 2026: Key Insights In RCC, Merkel Cell Carcinoma, and CML
▶︎
Adjuvant Durvalumab and the Future of Early-Stage NSCLC
▶︎
Landing without flaps! A340 with technical issues! AeroNews
▶︎
Emergency rooms at their limit: Overwhelmed by record surge? | stern TV
▶︎
Episode 1: Are We Ready for Biology Driven Bladder Cancer Care
▶︎
How Trauma Teaches You to Tolerate Disrespect (and How to Unlearn It) | Brené Brown Motivation
▶︎
Chemo Free or Chemo First Navigating Lu-PSMA-617, Radium, and Treatment Sequencing
▶︎
EV-302: advancing treatment for metastatic urothelial carcinoma
▶︎
Phase 2 Study of Multi-Cancer Detection from Breath Samples
▶︎
Choosing Between Abiraterone and Novel ARPIs: Practical Insights
▶︎
Oncology Bytes: Key Practice-Changing Updates from ASCO 2026 with Dr. Shaqil Kassam
▶︎
Balancing Efficacy and Safety: Toxicity, Patient Selection, and the Future of Ivonescimab
▶︎
Vorhofflimmern: Häufig, aber gut zu behandeln
▶︎